Eurosets has launched the U.S. commercialization of its cutting-edge Trilly and Horizon oxygenators after securing FDA 510(k) clearance, marking a major stride in critical care support technology and medical device availability across American hospitals. The company also inaugurated an exclusive U.S. partnership with Orion Medical, aligning distribution and clinical support efforts to address growing demand for dependable oxygenation solutions in complex cardiopulmonary procedures.
This expansion enables the Italian medical device manufacturer to bring Trilly and Horizon directly into a highly receptive U.S. market, where clinicians are seeking trauma-ready, high-performance cardiopulmonary bypass equipment to improve outcomes for patients facing heart and lung bypass needs, from neonates to adults. The launch underscores Eurosets’ steadfast commitment to patient-centric innovation and enhanced clinical outcomes.
Both products feature integrated stainless steel heat exchangers and are fully coated with Phosphorylcholine, boosting biocompatibility while enabling prolonged cardiopulmonary bypass procedures lasting up to six hours. Trilly is tailored for smaller patients requiring up to 3.5 L/min blood flow, whereas Horizon is designed to support adult and small adult patients with flows up to 7.0 L/min.
The oxygenators address critical health priorities by improving efficiency and reliability during complex surgical procedures commonly encountered in intensive care and cardiothoracic surgery environments. The oxygenator market grows due to rising atrial fibrillation prevalence, increased awareness and screening, and expanding adoption of advanced technologies, driving demand for efficient, safe, and reliable oxygenation solutions in healthcare.
In conjunction with the product launch, Eurosets formalised a strategic distribution partnership with Orion Medical, based in Detroit, Michigan, which will exclusively market the devices across the United States. Orion Medical is recognised for advanced medical technology distribution and for data-driven clinical solutions, bringing deep market expertise to support perfusion teams nationwide. Together, Eurosets and Orion are positioned to ensure seamless access to these essential oxygenation tools while anticipating future clinical demands.
“We are excited to begin serving the U.S. perfusion community with Trilly and Horizon,” said Davide Ariosto, Director of Global Sales and President of North America at Eurosets. Ariosto emphasized that collaboration with the FDA and clinical stakeholders has been constructive, fostering a strong launch foundation that the company expects to build on with future cardiopulmonary innovations. He reaffirmed Eurosets’ mission: every patient, whether newborn or adult, deserves the best chance of survival, whether in the hospital or the field.
Orion Medical’s Jeff Hanna, U.S. National Sales Director, echoed this optimism, highlighting that the alliance signifies a pivotal moment for advancing care in cardiovascular surgery and intensive care settings throughout the U.S. He noted that joining forces with Eurosets reflects a mutual conviction that innovation, service excellence, and robust clinical insights are essential in improving outcomes for critically ill patients.
The partnership and product rollout arrive amid a critical period when healthcare providers continue to face rising demands for high quality oxygenation solutions and life support devices, particularly as cardiovascular and respiratory procedures increase in complexity. Hospital perfusion teams are under mounting pressure to access cutting-edge tools that reduce procedural risks and improve patient stability during bypass and other extracorporeal interventions.
In preparation for broader engagement with the clinical community, Eurosets and Orion Medical are jointly attending the AmSECT Conference in Austin, Texas, from March 25 to 29. This premier event for perfusion professionals will provide a platform to demonstrate the Trilly and Horizon oxygenators, share clinical data, and engage directly with U.S. perfusionists and surgeons interested in integrating the devices into their procedural workflows.
Eurosets’ expansion into the U.S. follows several years of global growth and product evolution. The company, headquartered in Medolla, Italy, has established itself as a leader in advanced cardiopulmonary and extracorporeal life support devices, emphasizing biocompatibility, usability, and clinical performance. Its broader portfolio includes oxygenators, extracorporeal life support systems, and specialized components that collectively aim to improve perioperative and critical care outcomes.
By launching Trilly and Horizon in the U.S. and solidifying a trusted distribution network with Orion Medical, Eurosets is strengthening its commitment to frontline clinicians confronting life threatening conditions. The strategic initiative holds promise for improving perfusion practice standards and ensuring that performance?driven technology is available where it’s needed most, offering clinicians enhanced control and patients a better chance of recovery.
Looking ahead, Eurosets plans to leverage the partnership and U.S. presence to support additional clinical introductions and innovations, continually advancing technologies that align with evolving healthcare needs and reinforce its mission of patient centered excellence in critical care.
